Denmark spends less on medicine than in other European countries

29 January 2024
denmark-big

A response from the Ministry of the Interior and Health confirms that Denmark – compared to other European countries – has lower medical expenses per inhabitant, according to Danish pharm trade group Lif.

In both Greece and Portugal, more money is spent on medicine per per capita than in Denmark. This appears from a response from the Ministry of the Interior and Health. The calculation is based on OECD figures from 2022, which also document that in Denmark a smaller part of GDP is spent on medicine in 2022 compared to 2010.

"It is not new to us that Danish medical expenses are very low. On the contrary, it is something we have pointed to for years. But that is precisely why we are pleased that the government is now also helping to clear up the misunderstandings that have been around medicine costs," says Ida Sofie Jensen, chief executive of the Pharmaceutical Industry Association Lif.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical